Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from VIR

The origin of the Porsche 911 GT3 Rawr, IMSA’s wildest livery

According to recent paleontological studies, the Tyrannosaurus Rex was not a fast creature, with a maximum running speed potentially as slow as 10 m.p.h. Rexy, the current points leader in IMSA’s GTD Pro field, is much much quicker.

Watch A Suzuki GS450 Racing Mower Take Its First Laps On The VIR Kart Track

Watch A Suzuki GS450 Racing Mower Take Its First Laps On The VIR Kart Track

Stuffing a Suzuki GS450 engine and gearbox into a racing lawn mower/go kart build is cool, but getting test time in at a kart track will help with fine-tuning.

Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth

Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth

Vir Biotechnology obliterated expectations for its Covid drug in the third quarter, and Vir stock leaped above its 200-day line.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It

Vir Biotechnology inked a deal Tuesday worth up to $1 billion for its experimental flu treatment, leading Vir stock to surge.

Investors Business Daily

Raikkonen tests Trackhouse NASCAR Next Gen car at VIR ahead of Cup debut

Kimi Raikkonen got his first taste of a NASCAR Next Gen car at VIRginia International Raceway today, ahead of his Cup Series debut at Watkins Glen next weekend.

3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty

Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ:VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline,…

inkl

Read news from The Economist, FT, and more,
with one subscription

Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline

Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline

Recently, Vir Biotechnology Inc (NASDAQ:VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), and VIR-3434, a monoclonal antibody (mAb). The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with…

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here

The U.S. health regulator said GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) antibody therapy was no longer authorized as a COVID-19 treatment. The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide. "Sotrovimab is no longer authorized to treat COVID-19 in any…

Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility

Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility

GlaxoSmithKline's Covid treatment partner, Vir, will join the S&P SmallCap 600 next week, according to a report that sent Vir stock flying.

Investors Business Daily

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK…

GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows

GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows

According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. "These data show the persistence…

Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant

Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant

In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc (NYSE

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

TrackHouse Racing

Securities and Exchange Commission

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

250,916 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play